Ocugen, a biotech leader in gene therapies for blindness, announced presentations by its CEO and EVP at two key industry conferences in April 2026: Oppenheimer’s Innovation on the Island in Puerto Rico and the Cell & Gene Meeting on the Mediterranean in Rome. The company will highlight its gene-agnostic modifier gene therapy platform targeting major blindness diseases, with a planned Biologics License Application (BLA) submission for OCU400 later this year. These events offer Ocugen opportunities to update investors and partners on its progress toward commercializing novel treatments for inherited retinal diseases and other blindness conditions.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
Ramsdens Holdings PLC shares rose 13.6% to 670p following an improved takeover offer from US pawnbroking group FirstCash. FirstCash increased its cash bid to 675p per share from 600p, raising the total offer value to up to £232 million, including div...
